The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis

Inclusion Criteria: * Patients with interphalangeal hand OA (according to the EULAR classification criteria 2023) based on patient report (age, morning stiffness) and radiographs of ≤6 months old (osteophytes, JSN (joint space narrowing) and symptom-structure concordance (present if majority (≥50%) of the symptomatic joints demonstrate radiographic findings)). * Age ≥ 16 years * Have hand pain \>40mm on a 100mm visual analogue scale (VAS) * Have previously experienced failure of at least one conventional type of pain medication, (self-reported of insufficient effect from topical or oral NSAID, etc. with exclusion of paracetamol) Exclusion Criteria: * Comorbidity * Chronic inflammatory (rheumatic) diseases * Infectious diseases * Known Osteoporosis * Known Diabetes * Previous diagnosis of fibromyalgia * Known myasthenia gravis * Previous surgical interventions on the hand (e.g. carpal tunnel syndrome, etc.) * Use of other Medication: In order to maximize the generalizability of the study interactions between methylprednisolone and co-medication is only prohibited when the Dutch Medication Surveillance System (Z-index) gives a signal for this interaction. * Patients with a contraindication for MP * Current Gastric and duodenal ulcers * Current infections * Liver cirrhosis * Pregnant or breastfeeding * Known non-response or intolerance for MP * Not able to read or write the Dutch language * Neurological diagnosis * Epilepsy * Risk of psychiatric disorder